AZN Astrazeneca Plc

11,988.00

-38.00 (-0.32%)

26 Apr 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Astrazeneca Plc	LSE:AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-38.00	-0.32%	11,988.00	12,014.00	12,018.00	12,144.00	11,882.00	12,070.00	2,340,814	16:35:09

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	45.81B	5.96B	3.8415	31.28	186.27B

AstraZeneca's New Diabetes Drug Formulation Gets FDA Approval

23/10/2017 7:48am

Dow Jones News

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Apr 2019 to Apr 2024

   By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) has received approval from the U.S. Food and Drug Administration for a new formulation of its type-2 diabetes treatment option Bydureon, it said Monday.

The pharmaceutical company said that the regulator has given the green light to its Bydureon BCise injectable suspension drug--a single-dose autoinjector device that is used once a week. The new formulation reduces blood sugar levels and has the added benefit of weight loss, the company said.

AstraZeneca said the drug will be available to U.S. patients from the first quarter of 2018.

The European Medicines Agency has also accepted an application for the autoinjection, it added.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

October 23, 2017 02:33 ET (06:33 GMT)